A Meta-Analysis of the Association of N-Acetyltransferase 2 Gene (NAT2) Variants with Breast Cancer
Open Access
- 29 May 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 166 (3) , 246-254
- https://doi.org/10.1093/aje/kwm066
Abstract
The N-acetyltransferase 2 gene (NAT2) product is an enzyme important in carcinogen metabolism via activation and detoxification pathways. Therefore, NAT2 variants may represent underlying susceptibility to breast cancer. Because a number of studies of the association of NAT2 with breast cancer have been published, the authors performed a meta-analysis. They extracted all relevant data to examine evidence for a main effect (i.e., the effect in a model that does not include any interactions) of NAT2 phenotype and genotype on breast cancer risk. They summarized the evidence for modification by smoking and meat intake, sources of exposure to aromatic and heterocyclic amines, respectively, which are metabolized by NAT2. The authors identified seven studies that measured NAT2 phenotype and 20 studies that deduced phenotype via genotyping. They found no evidence for heterogeneity (Cochran's Q statistic p = 0.74) and no statistically significant increased risk from NAT2 acetylation (slow/rapid) for breast cancer (summary odds ratio = 1.02, 95% confidence interval: 0.95, 1.08). These results suggest that there is no overall association between the NAT2 slow- or rapid-acetylation phenotype and breast cancer risk. However, some evidence suggests that smoking may modify this association.Keywords
This publication has 36 references indexed in Scilit:
- Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands)Cancer Causes & Control, 2005
- NAT2 slow acetylator genotype as an important modifier of breast cancer riskInternational Journal of Cancer, 2004
- N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancerCancer Detection Prevention, 2004
- Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotypePharmacogenetics, 2000
- The Association of Polymorphic N‐Acetyltransferase (NAT2) with Breast Cancer RiskAnnals of the New York Academy of Sciences, 1995
- Genetic Analysis of the Arylamine N-Acetyltransferase Polymorphism in Breast Cancer PatientsOncology, 1995
- Genetic polymorphisms in xenobiotic metabolismEuropean Journal Of Cancer, 1994
- Acetylator status and its relationship to breast cancer and other diseases of the breastEuropean Journal of Cancer and Clinical Oncology, 1987
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Acetylator Phenotype in Patients with Breast CancerOncology, 1978